Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Total Liabilities (2016 - 2025)

Rein Therapeutics filings provide 10 years of Total Liabilities readings, the most recent being $7.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 7.16% year-over-year to $7.2 million, compared with a TTM value of $7.2 million through Dec 2025, down 7.16%, and an annual FY2025 reading of $7.2 million, down 7.16% over the prior year.
  • Total Liabilities hit $7.2 million in Q4 2025 for Rein Therapeutics, down from $7.5 million in the prior quarter.
  • The five-year high for Total Liabilities was $9.5 million in Q2 2025, with the low at $1.2 million in Q2 2023.
  • Median Total Liabilities over the past 5 years was $4.9 million (2021), compared with a mean of $5.6 million.
  • The sharpest move saw Total Liabilities crashed 76.76% in 2023, then soared 600.0% in 2024.
  • Year by year, Total Liabilities stood at $4.6 million in 2021, then fell by 26.07% to $3.4 million in 2022, then skyrocketed by 127.87% to $7.7 million in 2023, then grew by 1.13% to $7.8 million in 2024, then dropped by 7.16% to $7.2 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $7.2 million, $7.5 million, and $9.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.